(Q54596995)

1 June 2018

title

Everolimus Augments the Effects of Sorafenib in a Syngeneic Orthotopic Model of Hepatocellular Carcinoma (English)

1 reference

Crossref

DOI

https://api.crossref.org/works/10.1158/1535-7163.MCT-10-0666

29 November 2024

Ruslan Hlushchuk

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A21487053

29 November 2024

Luigi Terracciano

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A21487053

29 November 2024

Valentin Djonov

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A21487053

29 November 2024

Jean-François Dufour

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A21487053

29 November 2024

author name string

Anne-Christine Piguet

1 reference

1 June 2018

Bettina Saar

1 reference

1 June 2018

Vesna Radojevic

1 reference

1 June 2018

Maresa Afthinos

1 reference

1 June 2018

Marie V. St-Pierre

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A21487053

29 November 2024

Paul M. J. McSheehy

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A21487053

29 November 2024

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=21487053

29 November 2024

publication date

12 April 2011

1 reference

1 June 2018

full work available at URL

published in

Molecular Cancer Therapeutics

1 reference

1 June 2018

volume

1 reference

1 June 2018

issue

1 reference

1 June 2018

page(s)

1007-1017

1 reference

1 June 2018

Sorafenib in advanced hepatocellular carcinoma

cites work

1 reference

https://api.crossref.org/works/10.1158/1535-7163.MCT-10-0666

Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial

29 November 2024

1 reference

https://api.crossref.org/works/10.1158/1535-7163.MCT-10-0666

Ubiquitous activation of Ras and Jak/Stat pathways in human HCC.

29 November 2024

1 reference

https://api.crossref.org/works/10.1158/1535-7163.MCT-10-0666

BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis

29 November 2024

1 reference

https://api.crossref.org/works/10.1158/1535-7163.MCT-10-0666

The role of signaling pathways in the development and treatment of hepatocellular carcinoma

29 November 2024

1 reference

https://api.crossref.org/works/10.1158/1535-7163.MCT-10-0666

Vascular remodeling and antitumoral effects of mTOR inhibition in a rat model of hepatocellular carcinoma

29 November 2024

1 reference

https://api.crossref.org/works/10.1158/1535-7163.MCT-10-0666

Sorafenib and rapamycin induce growth suppression in mouse models of hepatocellular carcinoma

29 November 2024

1 reference

https://api.crossref.org/works/10.1158/1535-7163.MCT-10-0666

A reproducible rat liver cancer model for experimental therapy: introducing a technique of intrahepatic tumor implantation

29 November 2024

1 reference

https://api.crossref.org/works/10.1158/1535-7163.MCT-10-0666

Optimality in the developing vascular system: branching remodeling by means of intussusception as an efficient adaptation mechanism

29 November 2024

1 reference

https://api.crossref.org/works/10.1158/1535-7163.MCT-10-0666

Protein measurement with the Folin phenol reagent

29 November 2024

1 reference

https://api.crossref.org/works/10.1158/1535-7163.MCT-10-0666

Mammalian target of rapamycin pathway activity in hepatocellular carcinomas of patients undergoing liver transplantation

29 November 2024

1 reference

https://api.crossref.org/works/10.1158/1535-7163.MCT-10-0666

Pivotal role of mTOR signaling in hepatocellular carcinoma

29 November 2024

1 reference

https://api.crossref.org/works/10.1158/1535-7163.MCT-10-0666

Transcriptome classification of HCC is related to gene alterations and to new therapeutic targets

29 November 2024

1 reference

https://api.crossref.org/works/10.1158/1535-7163.MCT-10-0666

Ras pathway activation in hepatocellular carcinoma and anti-tumoral effect of combined sorafenib and rapamycin in vivo

29 November 2024

1 reference

https://api.crossref.org/works/10.1158/1535-7163.MCT-10-0666

Effect of rapamycin alone and in combination with sorafenib in an orthotopic model of human hepatocellular carcinoma

29 November 2024

1 reference

https://api.crossref.org/works/10.1158/1535-7163.MCT-10-0666

Angiogenesis and hepatocellular carcinoma

29 November 2024

1 reference

https://api.crossref.org/works/10.1158/1535-7163.MCT-10-0666

Efficacy, safety, and potential biomarkers of sunitinib monotherapy in advanced hepatocellular carcinoma: a phase II study

29 November 2024

1 reference

https://api.crossref.org/works/10.1158/1535-7163.MCT-10-0666

Vascular endothelial growth factor inhibition: conflicting roles in tumor growth

29 November 2024

1 reference

https://api.crossref.org/works/10.1158/1535-7163.MCT-10-0666

mTOR inhibitor RAD001 (everolimus) has antiangiogenic/vascular properties distinct from a VEGFR tyrosine kinase inhibitor

29 November 2024

1 reference

https://api.crossref.org/works/10.1158/1535-7163.MCT-10-0666

Biomarker Development for the Clinical Activity of the mTOR Inhibitor Everolimus (RAD001): Processes, Limitations, and Further Proposals

29 November 2024

1 reference

https://api.crossref.org/works/10.1158/1535-7163.MCT-10-0666

Deregulation of the PI3K and KRAS signaling pathways in human cancer cells determines their response to everolimus

29 November 2024

1 reference

https://api.crossref.org/works/10.1158/1535-7163.MCT-10-0666

Studies on the mechanism of resistance to rapamycin in human cancer cells

29 November 2024

1 reference

https://api.crossref.org/works/10.1158/1535-7163.MCT-10-0666

Oncogene expression in rat hepatomas and during hepatocarcinogenesis

29 November 2024

1 reference

https://api.crossref.org/works/10.1158/1535-7163.MCT-10-0666

Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling

29 November 2024

1 reference

https://api.crossref.org/works/10.1158/1535-7163.MCT-10-0666

Vascular endothelial growth factor regulates endothelial cell survival through the phosphatidylinositol 3'-kinase/Akt signal transduction pathway. Requirement for Flk-1/KDR activation

29 November 2024

1 reference

https://api.crossref.org/works/10.1158/1535-7163.MCT-10-0666

mTOR inhibition by everolimus counteracts VEGF induction by sunitinib and improves anti-tumor activity against gastric cancer in vivo

29 November 2024

1 reference

https://api.crossref.org/works/10.1158/1535-7163.MCT-10-0666

Increased AKT S473 phosphorylation after mTORC1 inhibition is rictor dependent and does not predict tumor cell response to PI3K/mTOR inhibition

29 November 2024

1 reference

https://api.crossref.org/works/10.1158/1535-7163.MCT-10-0666

Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer

29 November 2024

1 reference

https://api.crossref.org/works/10.1158/1535-7163.MCT-10-0666

Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis

29 November 2024

1 reference

https://api.crossref.org/works/10.1158/1535-7163.MCT-10-0666

Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis

29 November 2024

1 reference

https://api.crossref.org/works/10.1158/1535-7163.MCT-10-0666

29 November 2024

Identifiers

DOI

1 reference

1 June 2018

1 reference

1 June 2018